Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

In patients with stable cardiovascular disease, those receiving rivaroxaban plus aspirin had fewer major cardiovascular events but more major bleeding events than those receiving aspirin alone. Rivaroxaban alone did not result in fewer major cardiovascular events than aspirin alone.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2017-10, Vol.377 (14), p.1319-1330
Hauptverfasser:	Eikelboom, John W, Connolly, Stuart J, Bosch, Jackie, Dagenais, Gilles R, Hart, Robert G, Shestakovska, Olga, Diaz, Rafael, Alings, Marco, Lonn, Eva M, Anand, Sonia S, Widimsky, Petr, Hori, Masatsugu, Avezum, Alvaro, Piegas, Leopoldo S, Branch, Kelley R.H, Probstfield, Jeffrey, Bhatt, Deepak L, Zhu, Jun, Liang, Yan, Maggioni, Aldo P, Lopez-Jaramillo, Patricio, O’Donnell, Martin, Kakkar, Ajay K, Fox, Keith A.A, Parkhomenko, Alexander N, Ertl, Georg, Störk, Stefan, Keltai, Matyas, Ryden, Lars, Pogosova, Nana, Dans, Antonio L, Lanas, Fernando, Commerford, Patrick J, Torp-Pedersen, Christian, Guzik, Tomek J, Verhamme, Peter B, Vinereanu, Dragos, Kim, Jae-Hyung, Tonkin, Andrew M, Lewis, Basil S, Felix, Camilo, Yusoff, Khalid, Steg, P. Gabriel, Metsarinne, Kaj P, Cook Bruns, Nancy, Misselwitz, Frank, Chen, Edmond, Leong, Darryl, Yusuf, Salim
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anticoagulants Arteriosclerosis Aspirin Aspirin - adverse effects Aspirin - therapeutic use Atherosclerosis Atherosclerosis - complications Atherosclerosis - drug therapy Bleeding Cardiovascular disease Cardiovascular Diseases - drug therapy Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control Cerebral infarction Coronary vessels Disease prevention Double-Blind Method Drug dosages Drug therapy Drug Therapy, Combination Factor Xa Inhibitors - adverse effects Factor Xa Inhibitors - therapeutic use Female Hemorrhage - chemically induced Human health and pathology Humans Life Sciences Male Medical research Middle Aged Myocardial infarction Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Rivaroxaban - adverse effects Rivaroxaban - therapeutic use Secondary Prevention - methods
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In patients with stable cardiovascular disease, those receiving rivaroxaban plus aspirin had fewer major cardiovascular events but more major bleeding events than those receiving aspirin alone. Rivaroxaban alone did not result in fewer major cardiovascular events than aspirin alone.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1709118